Navigation Links
Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
Date:10/16/2007

us complications such as muscle weakness and breathing difficulties. NMBAs are often administered during surgery to enable endotracheal intubation and provide total skeletal muscle relaxation when the surgery requires that patients' muscles are relaxed during the procedure.

Professor Caldwell added, "Also, the results of the Spectrum trial are important because it indicates that the combination of rocuronium followed by sugammadex can provide faster recovery from neuromuscular blockade than spontaneous recovery from succinylcholine, the shortest acting NMBA currently available."

About the Signal trial(1)

This profound block trial was a multicenter, parallel-group study among adult patients undergoing surgery in the supine position (patient on his/her back). Rocuronium (0.6 mg/kg) was administered for intubation, followed by maintenance doses (0.15 mg/kg) as required. When reversal was needed, patients were randomized to receive either sugammadex (4.0 mg/kg) or neostigmine (70 micrograms/kg) plus glycopyrrolate (14 micrograms/kg).

In the intent-to-treat population (37 patients in each group), the mean time to recovery of the T(4)/T(1) ratio to 0.9 with sugammadex was 2.9 minutes, compared to 50.4 minutes with neostigmine/glycopyrrolate (p< 0.0001), a confirmed 17 times faster reversal with sugammadex.

The most frequently reported adverse events (AEs) for the sugammadex and neostigmine groups regardless of relationship to the study drug were procedural pain (70 vs. 76%) and nausea (38 vs. 50%). For both groups no serious drug-related adverse events were reported. Clinical chemistry results were similar between groups. No patients had clinical evidence of recurarization or residual curarization.

About the Spectrum trial(2)

In this second profound block trial, 110 patients undergoing elective surgery requiring short duration of neuromuscular relaxation were randomized to receive either an intubating dose of rocuronium 1.2 mg/kg
'/>"/>

SOURCE Organon
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
2. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
3. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
4. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
5. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
6. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research ... and Drug Administration (FDA) has given the company permission ... AS2-1 in patients > 3 months of age with ... be placed in one of five treatment groups based ... received prior treatment for DIPG. The primary study endpoint ...
(Date:10/25/2014)... N.C. , Oct. 24, 2014  As ... can provide a company access to diverse skill ... markets, and round-the clock business hours for efficiency. ... difficult hurdles. According to recent ... disappointments, such as seeing a project not move ...
(Date:10/22/2014)...  Cephasonics, a technology-innovation leader with a game-changing embedded-ultrasound ... Ultrasound Box™-1), the first product in a new family ... Cephasonics for purchase by companies to rebrand with their ... showcasing the cQUB-1 for the first time at CMEF ... Chongqing, China from October 23 to 26. ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3
... April 27, 2011 ACCESS PHARMACEUTICALS, ... leveraging its proprietary drug-delivery platforms to develop treatments in areas ... Nursing Society (ONS) Congress at the Boston Convention and Exhibition ... (#652) will be displayed in the Exhibition Hall of the ...
... PharmaTech (Cayman) Inc. (NYSE: WX ) today ... 20-F for the year ended December 31, 2010 with ... be accessed on WuXi PharmaTech,s website at http://www.wuxiapptec.com ... provide a hard copy of its annual report on ...
Cached Medicine Technology:Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 2Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 3
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for ... prices. Bob Seger & The Silver Bullet Band tickets ... are going on sale October 25 and are expected ... browse the selection of tickets for Bob Seger & ... singer is touring North America beginning next month, and ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in a ... his combination drug therapy became too toxic. Click ... on the Surviving Mesothelioma website. , A new ... suggests that “maintenance therapy” with pemetrexed may be the ... higher doses of cisplatin. , “Although the standard ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... sores -- herpes simplex -- might increase the risk of ... fact, being a carrier of certain antibodies to the virus ... "The identification of a treatable cause [herpes simplex] ... lead researcher Dr. Hugo Lovheim, an associate professor in the ...
(Date:10/25/2014)... (HealthDay News) -- A large influx of international aid ... avoid tens of thousands of deaths from the widening ... Using a specially designed mathematical model, the ... in just one densely populated county of hard-hit Liberia ... Monrovia. The researchers said that if international aid ...
(Date:10/25/2014)... shorter, darker days can trigger a type of depression, ... People affected by seasonal affective disorder, also ... even have trouble getting out of bed. In extreme ... Halaris, a professor in the department of psychiatry and ... Medicine. "Seasonal affective disorder should not be taken ...
Breaking Medicine News(10 mins):Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... Steve Pasierb, President , , ... (MTF) indicates the continuation of a promising trend of declining usage ... crack -- among our country,s teens. However, it also indicates several ... Progress , The long-term ...
... and Uplifting TV Movie Portrayal of Tourette Syndrome , ... Nearly 12 million people watched last Sunday night,s Hallmark Hall ... movie based on the true story of a young man,s ... an award winning teacher. The national Tourette Syndrome Association, ...
... - Scientists in the clinic and the laboratory continue ... with breakthrough drugs. With tamoxifen,s discovery 30 years behind ... researchers are studying zoledronic acid, aromatase inhibitors and monoclonal ... presented at the CTRC-AACR San Antonio Breast Cancer Symposium. ...
... Sister Carol Keehan, DC, president and chief executive officer ... issued the following statement: , , ... nomination today of former Senate Majority Leader Tom Daschle to ... person to oversee a new White House Office of Health ...
... The following is a statement by Matthew L. Myers, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) , ... health that the 2008 Monitoring the Future survey released today ... have declined to the lowest levels recorded in this survey ...
... DNA, study says , , THURSDAY, Dec. 11 (HealthDay ... of DNA damage from prolonged exposure to cosmic ionizing ... pilots to 50 university faculty members from the same ... analyzed for DNA abnormalities, specifically the number of times ...
Cached Medicine News:Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 3Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:Cancer drugs in the pipeline 2Health News:Catholic Health Association Statement on the Naming of Tom Daschle and Jeanne Lambrew to Health Leadership Positions in President-Elect Obama's Administration 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 3Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 4Health News:Pilots May Face Greater Cancer Risk 2
... high-quality light guide cables work in conjunction ... optimal brightness during a number of procedures. ... you the flexibility and ease-of-use necessary to ... fully-autoclavable so they can be easily cleaned ...
... line of affordable, high-quality light guide cables ... sources to provide optimal brightness during a ... durable design give you the flexibility and ... And each is fully-autoclavable so they can ...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
Medicine Products: